Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.Nature Communications|January 31, 2026
Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trialZev A Wainberg, Jason M Link, Alykhan Premji, et al.The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 StudyKohei Shitara, Sylvie Lorenzen, Jin Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRonan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.Pageof 14